all updates

SES launches first accredited CME event

June 23, 2022

SES is excited to the announce the accreditation of its first continuing medical education (CME) event. As part of our range of bespoke education programs, we are launching a clinical trial club in myeloproliferative neoplasms (MPN) entitled “Novel agents for the treatment of advanced myelofibrosis (MF).” The first interactive discussion for the club, “BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/refractory MF,” will be accessible as a live webinar on July 19, 2022, 08:00 CST (15:00 CEST). This 60-minute event has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. The EBAC has signed agreements with the majority of European countries and an agreement of mutual recognition of credits with the American Medical Association (AMA), providing opportunities for physicians and teams to participate in high-quality CME around the world. By launching accredited education, it is our aim to provide healthcare professionals with education that will maintain and improve standards of medical practice, ultimately improving patient outcomes, globally. 

What is accreditation and why is it important? 

Accreditation is the process by which a credible, independent body assesses the quality of a medical education program to provide assurance that it is appropriate, balanced, transparent, and effective. Many countries require healthcare professionals to partake in accredited CME activities throughout their career for maintenance of licensure and certification, membership of professional societies, and other professional privileges. The EBAC awards continuing education points as a sign of quality and independence for participation in educational activities. It’s accreditation system requires CME providers to base their education on a needs assessment, measure the effectiveness of their educational activities, design educational content that meets accepted standards of scientific integrity, and ensure that education is free of commercial bias and influence. SES is pleased to have met the requirements of this rigorous evaluation process with the design of its first CME event. Looking to the future, we aim to establish a portfolio of CME resources for healthcare professionals across our therapy areas of focus. 

Our first CME event 

Our first CME event is brought to you via the expertise of the MPN Hub

Myelofibrosis is associated with a significant reduction in patients' quality of life and an increased risk of mortality. Available treatment options, excluding allogeneic stem cell transplantation, are mainly directed to disease-related symptoms and splenomegaly. While JAK inhibitors provide spleen control and symptom improvement for patients, response to treatment is often lost, and there is currently an unmet need for novel therapies to effectively target the disease at the level of the malignant stem cell. There is an ongoing effort to develop novel approaches with different modes of action to fulfil this need, and with such progress it is key that healthcare professionals understand novel targets, the mechanisms of action of new agents, and maintain up-to-date knowledge of the role of new agents in the therapeutic landscape. 

In this first clinical trial club, chaired by Laura Michaelis, trial investigator Haifa Kathrin Al-Ali will discuss the phase II and phase III clinical trials (NCT03662126) investigating the novel MDM2 inhibitor, navtemadlin (KRT-232), in patients with MF who relapsed on or are refractory to JAK inhibitors. Together, they will review results from the open-label phase II trial and consider what these findings and the ongoing randomized controlled phase III trial (BOREAS), investigating navtemadlin versus best available therapy in relapsed/refractory MF, mean for clinical practice. The agenda includes a live question and answer session, providing participants with the opportunity to interact with our world-renowned faculty. A pre- and post-event test will allow us to understand the outcomes of this event and will help inform the design of future education.  

MPN CTC Bolt-on social_4.png

Registration is now live! Sign up now to secure your place.


Sign Up For Our Monthly Newsletter

Looking to receive the latest news, project updates, and new offerings?